THE USE OF TWICE-DAILY NEDOCROMIL SODIUM IN THE TREATMENT OF ASTHMA

被引:19
作者
CRETICOS, P
BURK, J
SMITH, L
COMP, R
NORMAN, P
FINDLAY, S
机构
[1] PULM CONSULTANTS TEXAS PA,FT WORTH,TX
[2] NORTHWESTERN UNIV,SCH MED,DEPT MED,DIV PULM,CHICAGO,IL 60611
[3] PULM ASSOCIATES PA,PHOENIX,AZ
[4] HLTH QUEST THERAPY & RES INST INC,AUSTIN,TX
关键词
ASTHMA; ANTIINFLAMMATORY; PYRANOQUINOLINE; NEDOCROMIL SODIUM; TWICE DAILY DOSING;
D O I
10.1016/S0091-6749(95)70126-5
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
The efficacy and safety of nedocromil sodium inhalation aerosol (4 mg* of Tilade administered by metered-dose inhaler) given twice daily was compared with placebo in 112 patients with mild-to-moderate asthma who had been receiving maintenance therapy with oral or inhaled bronchodilators or both. After a 2-week run-in period and a subsequent 2-week baseline period, patients were randomized to active treatment (n = 56) or placebo (n = 56) for 8 weeks. All maintenance bronchodilators were withdrawn before the baseline period, and patients entered the treatment period only after demonstrating a specified level of asthma symptoms. Twice daily administration of nedocromil sodium improved all asthma symptoms in these patients who had symptoms as a result of the withdrawal of their maintenance theophylline and/or and inhaled beta(2)-agonist bronchodilators. During the primary time period (treatment weeks 5 to 8), statistically significant between-group differences favored nedocromil sodium for the asthma summary score (primary variable, p = 0.001), daytime asthma (p = 0.001), and sleep difficulty caused by asthma (p = 0.006). Furthermore, significant reductions in the use of as-needed rescue medications were reported in the nedocromil sodium group (p = 0.003) compared with the placebo group. Final overall opinions of treatment effectiveness expressed by physicians (p = 0.016) and patients (p = 0.002) strongly favored nedocromil sodium.
引用
收藏
页码:829 / 836
页数:8
相关论文
共 18 条
[1]   THE EFFECT OF NEDOCROMIL SODIUM ON THE EARLY AND LATE REACTION AND ALLERGEN-INDUCED BRONCHIAL HYPERRESPONSIVENESS [J].
AALBERS, R ;
KAUFFMAN, HF ;
GROEN, H ;
KOETER, GH ;
DEMONCHY, JGR .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1991, 87 (05) :993-1001
[2]   THE LONG-TERM EFFECTS OF NEDOCROMIL SODIUM AND BECLOMETHASONE DIPROPIONATE ON BRONCHIAL RESPONSIVENESS TO METHACHOLINE IN NONATOPIC ASTHMATIC SUBJECTS [J].
BEL, EH ;
TIMMERS, MC ;
HERMANS, J ;
DIJKMAN, JH ;
STERK, PJ .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (01) :21-28
[3]   NEDOCROMIL SODIUM - AN UPDATED REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY IN ASTHMA [J].
BROGDEN, RN ;
SORKIN, EM .
DRUGS, 1993, 45 (05) :693-715
[4]   EFFECTS OF THE ADDITION OF NEDOCROMIL SODIUM TO MAINTENANCE BRONCHODILATOR THERAPY IN THE MANAGEMENT OF CHRONIC ASTHMA [J].
CALLAGHAN, B ;
TEO, NC ;
CLANCY, L .
CHEST, 1992, 101 (03) :787-792
[5]  
CHERNIACK R M, 1990, Chest, V97, P1299
[6]  
COCHRANE GM, 1992, EUR RESPIR J, V5, P122
[7]   NEDOCROMIL SODIUM VERSUS ALBUTEROL IN THE MANAGEMENT OF ALLERGIC-ASTHMA [J].
DEJONG, JW ;
TEENGS, JP ;
POSTMA, DS ;
VANDERMARK, TW ;
KOETER, GH ;
DEMONCHY, JGR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (01) :91-97
[8]   ASSOCIATION BETWEEN AVAILABILITY OF NONPRESCRIPTION BETA(2) AGONIST INHALERS AND UNDERTREATMENT OF ASTHMA [J].
GIBSON, P ;
HENRY, D ;
FRANCIS, L ;
CRUICKSHANK, D ;
DUPEN, F ;
HIGGINBOTHAM, N ;
HENRY, R ;
SUTHERLAND, D .
BRITISH MEDICAL JOURNAL, 1993, 306 (6891) :1514-1518
[9]  
KOCH GG, 1990, STATISTICAL METHODOL, P201
[10]  
MARCOUX JP, 1992, EUR RESPIR J S15, V5, pS83